Brokerages Set Vera Therapeutics, Inc. (NASDAQ:VERA) Price Target at $77.18

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) have been assigned a consensus rating of “Moderate Buy” from the twelve brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $78.80.

A number of equities analysts have recently weighed in on VERA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Wednesday, January 21st. The Goldman Sachs Group upped their price objective on shares of Vera Therapeutics from $55.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Pivotal Research set a $73.00 target price on shares of Vera Therapeutics in a research report on Friday, December 5th. Evercore lifted their price objective on Vera Therapeutics from $75.00 to $97.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. Finally, TD Cowen restated a “buy” rating on shares of Vera Therapeutics in a research note on Friday, December 5th.

Vera Therapeutics Price Performance

Shares of NASDAQ:VERA opened at $40.79 on Wednesday. The company’s fifty day moving average is $46.32 and its two-hundred day moving average is $35.49. The company has a market cap of $2.86 billion, a P/E ratio of -8.75 and a beta of 1.16. Vera Therapeutics has a 12-month low of $18.53 and a 12-month high of $56.05. The company has a quick ratio of 12.21, a current ratio of 12.21 and a debt-to-equity ratio of 0.19.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.05). During the same quarter last year, the firm posted ($0.72) earnings per share. Equities analysts expect that Vera Therapeutics will post -2.89 earnings per share for the current fiscal year.

Insider Activity at Vera Therapeutics

In other news, SVP Joseph R. Young sold 3,117 shares of the business’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $130,851.66. Following the completion of the sale, the senior vice president directly owned 64,722 shares in the company, valued at approximately $2,717,029.56. The trade was a 4.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Sean Grant sold 4,949 shares of the company’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $207,759.02. Following the sale, the chief financial officer directly owned 114,181 shares of the company’s stock, valued at approximately $4,793,318.38. This represents a 4.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 33,490 shares of company stock worth $1,405,910 over the last quarter. 16.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its stake in shares of Vera Therapeutics by 49.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock worth $276,595,000 after purchasing an additional 1,795,537 shares during the period. Deerfield Management Company L.P. grew its holdings in Vera Therapeutics by 8.8% in the 3rd quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock valued at $105,812,000 after buying an additional 293,040 shares during the last quarter. Vanguard Group Inc. increased its position in Vera Therapeutics by 11.9% in the 4th quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock worth $180,805,000 after buying an additional 379,748 shares during the period. Vestal Point Capital LP lifted its holdings in shares of Vera Therapeutics by 24.0% during the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock worth $73,036,000 after buying an additional 600,000 shares during the last quarter. Finally, Eversept Partners LP lifted its holdings in shares of Vera Therapeutics by 9.4% during the fourth quarter. Eversept Partners LP now owns 3,072,304 shares of the company’s stock worth $155,581,000 after buying an additional 264,468 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.